Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 169

The DOI matches its Crossref record.

The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma

Open access
Xu, G. Wei, Ali, Mohsin, Wood, Tabitha E., Wong, Derek, Maclean, Neil, Wang, Xiaoming, Gronda, Marcela, Skrtic, Marko, Li, Xiaoming, Hurren, Rose, Mao, Xinliang, Venkatesan, Meenakshi, Zavareh, Reza Beheshti, Ketela, Troy, Reed, John C., Rose, David, Moffat, Jason, Batey, Robert A., Dhe-Paganon, Sirano, Schimmer, Aaron D. · 2010 · Blood

Abstract

The proteasomal pathway of protein degradation involves 2 discrete steps: ubiquitination and degradation. Here, we evaluated the effects of inhibiting the ubiquitination pathway at the level of the ubiquitin-activating enzyme UBA1 (E1). By immunoblotting, leukemia cell lines and primary patient samples had increased protein ubiquitination. Therefore, we examined the effects of genetic and chemical inhibition of the E1 enzyme. Knockdown of E1 decreased the abundance of ubiquitinated proteins in leukemia and myeloma cells and induced cell death. To further investigate effects of E1 inhibition in malignancy, we discovered a novel small molecule inhibitor, 3,5-dioxopyrazolidine compound, 1-(3-chloro-4-fluorophenyl)-4-[(5-nitro-2-furyl)methylene]-3,5-pyrazolidinedione (PYZD-4409). PYZD-4409 induced cell death in malignant cells and preferentially inhibited the clonogenic growth of primary acute myeloid leukemia cells compared with normal hematopoietic cells. Mechanistically, genetic or chemical inhibition of E1 increased expression of E1 stress markers. Moreover, BI-1 overexpression blocked cell death after E1 inhibition, suggesting ER stress is functionally important for cell death after E1 inhibition. Finally, in a mouse model of leukemia, intraperitoneal administration of PYZD-4409 decreased tumor weight and volume compared with control without untoward toxicity. Thus, our work highlights the E1 enzyme as a novel target for the treatment of hematologic malignancies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2009-07-231191

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 169

Metadata

Authors
Xu, G. W., Ali, M., Wood, T. E., Wong, D., Maclean, N., Wang, X., Gronda, M., Skrtic, M., Li, X., Hurren, R., Mao, X., Venkatesan, M., Zavareh, R. B., Ketela, T., Reed, J. C., Rose, D., Moffat, J., Batey, R. A., Dhe-Paganon, S., & Schimmer, A. D.
Venue
Blood
Published
2010-03-18
Volume
115
Issue
11
Pages
2251-2259
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2040146122
Cited by
169
References
0
FWCI
5.32
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. https://app.cochat.ai/papers/10.1182/blood-2009-07-231191
The paper
Xu, G. W., Ali, M., Wood, T. E., Wong, D., Maclean, N., Wang, X., Gronda, M., Skrtic, M., Li, X., Hurren, R., Mao, X., Venkatesan, M., Zavareh, R. B., Ketela, T., Reed, J. C., Rose, D., Moffat, J., Batey, R. A., Dhe-Paganon, S., & Schimmer, A. D. (2010). The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood. https://doi.org/10.1182/blood-2009-07-231191

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.